Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.
about
Modulation of microRNA expression by budesonide, phenethyl isothiocyanate and cigarette smoke in mouse liver and lungBudesonide in the treatment of inflammatory bowel disease.Colon delivery of budesonide using solid dispersion in dextran for the treatment and secondary prevention of ulcerative colitis in ratThe effect of budesonide on orthodontic induced root resorption.Optimizing management of distal ulcerative colitis.Protein-losing enteropathy after Fontan operation.Nonabsorbable corticosteroids use in the treatment of gastrointestinal graft-versus-host disease.Treatment of steroid-naive ulcerative colitis.Pharmacokinetics in special populations.Budesonide for Crohn's disease.Oral budesonide treatment for protein-losing enteropathy in Fontan-palliated patients.Glucocorticoid sensitivity in inflammatory bowel disease.Drug choices in autoimmune hepatitis: part A--Steroids.Emerging drugs for eosinophilic esophagitis.Eosinophils and mast cells as therapeutic targets in pediatric functional dyspepsiaNovel extended release budesonide formulation for treatment of ulcerative colitis.Perioperative corticosteroid management for patients with inflammatory bowel disease.Enteric-coated budesonide for the induction and maintenance of remission of Crohn's disease in children.Pharmacokinetic drug evaluation of budesonide in the treatment of Crohn's disease.Evolving paradigm of treatment for autoimmune hepatitis.Management of Eosinophilic Esophagitis During Pregnancy.Budesonide for the treatment of ulcerative colitis.Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).Approach to the Patient with Mild Crohn's Disease: a 2016 Update.Corticosteroid production in H295R cells during exposure to 3 endocrine disrupters analyzed with LC-MS/MS.Polymer-based drug delivery: the quest for local targeting of inflamed intestinal mucosa.Comparative efficacy of esomeprazole and omeprazole: Racemate to single enantiomer switch.Iatrogenic Cushing Syndrome from Interaction Between Ritonavir and Oral Budesonide During Direct Acting Antiviral Hepatitis C TherapyGastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulationBudesonide induction and maintenance therapy for Crohn's disease during pregnancy.Administration of budesonide in children with graft-versus-host disease.Evaluation of separate role of intestine and liver in first pass metabolism of budesonide in rat.The role of corticosteroids in celiac disease.Central Serous Chorioretinopathy in a Patient with Ulcerative Colitis with Pouchitis on Budesonide-EC.
P2860
Q33829198-36F7C9FA-186B-4FEC-8887-7EBD9084D2D4Q34203594-3DB22EAE-374A-41EA-8A76-B48C9F655479Q34786414-BBF9E55A-26CD-4697-8EA5-1FD97BF22370Q35942910-63B4090A-4714-4506-ACAE-B7DC9C3A366FQ36459902-937A2316-2687-460E-8D9C-2DC37D7D742BQ37123517-4BEB032B-57BA-4674-813E-C65A0767E265Q37414672-036E6E41-CDB6-404C-BADB-A6B8DA1B8417Q37483916-932CFEFD-B0AE-40DC-B14D-FC0B498D788DQ37550561-066FA9B0-F80A-43E5-909C-205F7B741AD9Q37554383-3839B9AE-1A01-4D86-B3DA-4C1889FA900FQ37887563-F1733F86-776E-484A-8D89-493483863B08Q37944911-41E0D706-B523-44D3-8253-3E52BEED4D35Q38051705-FB4EA26C-9EBE-4ABA-982E-054E73E334B6Q38128368-33FBAFB2-5257-48E9-9923-C0A035DFF517Q38160491-7C7CDEA0-DEB8-4D4B-A2E2-397B85A9EED7Q38161988-9E0BBE3E-F436-4BA0-823C-6D73407A306FQ38248114-72A2B569-3CF1-474D-83E8-717EFDBC657FQ38377938-1C20A11E-D89E-4FAF-AF5C-9928C7E3D993Q38726458-D0B2A189-1499-44F7-88FB-7B139092C6CCQ38730872-6765BF9C-05B3-449D-85A6-796356D12BB8Q38738250-2CC9A9A3-4F59-4DF0-B7C7-8DD5D0C1E4EFQ38828972-ED128C8A-11EB-481D-982F-18570DF8504FQ38855314-85C934BA-A383-4DEC-8CC6-B218B9481726Q38905783-081D3759-00B2-4F6A-9BF9-8DB4C21FB6B2Q39160964-881C96C6-60AB-46DC-A392-AFB3A0DD07B5Q39170844-B7B161A5-F635-4FAA-A23B-9A2773A73ED7Q40316973-85F8E970-8036-4AE1-8CA7-237914797169Q40539589-D410E95B-4C27-4186-A38C-B12ECC756130Q42758588-39390A98-4E48-41B7-911E-BBB9E49447CBQ44180072-172687A5-877F-44ED-A50A-37F180804199Q46519541-3F0C9C41-2C4D-4317-986A-C21AC1572A1BQ47429728-FD813CF0-B58C-4A2D-B398-5DE4B0BA852CQ50489393-CAA6F4EF-8390-457D-AD71-C821884BA3A1Q53412435-A4BD7AD8-E8A4-41D3-A378-7BBC8AFA7E84
P2860
Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.
@ast
Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.
@en
type
label
Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.
@ast
Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.
@en
prefLabel
Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.
@ast
Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.
@en
P1476
Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.
@en
P2093
Staffan Edsbäcker
Tommy Andersson
P304
P356
10.2165/00003088-200443120-00003
P577
2004-01-01T00:00:00Z
P6179
1005872497